The evaluation of clarithromycin (CAM) in bronchial epithelial lining fluid (ELF) using bronchoscopic microsampling (BMS) probes is useful in the management of patients with pulmonary <I>Mycobacterium avium</I> complex (MAC)

The evaluation of clarithromycin (CAM) in bronchial epithelial lining fluid (ELF) using bronchoscopic microsampling (BMS) probes is useful in the management of patients with pulmonary Mycobacterium avium complex (MAC)

T. Nishimura, N. Hasegawa, M. Watanabe, A. Ishizaka (Shinanomachi, Shinjuku, Japan)

Source: Annual Congress 2005 - Biological and treatment aspects of tuberculosis

Session: Biological and treatment aspects of tuberculosis
Session type: Poster Discussion
Number: 2904

Disease area: Respiratory infections

Abstract

Recently developed BMS probes has made it possible to measure the concentration of antimicrobial agents in bronchial ELF. We evaluated the concentration of CAM of ELFs obtained from both rentogenographically injured and uninjured pulmonary segments in reference to that of serum. We studied 8 patients of pulmonary MAC diagnosed on the criteria announced by ATS in 1997. They were further divided into two groups depending on the daily amounts of CAM, 400mg/day or 800mg/day without any concomitant medicine for 7 days prior to BMS procedure. The concentrations of CAM and 14-OH CAM in the ELF sampled from injured segment of the CAM 800mg/day group were significantly higher than those of the CAM 400mg/day group while the plasma concentrations of the both groups were not significantly different. In the CAM 800mg/day group combined concentrations of CAM and 14-OH CAM in the ELF obtained not only from injured segment but also from uninjured segment were higher than minimal inhibitory concentration (MIC) against MAC. These results suggest that CAM 800mg/day could be an appropriate amounts for treating pulmonary infectious sites with MAC as well as preventing spread of MAC from injured sites to uninjured pulmonary segments.

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Nishimura, N. Hasegawa, M. Watanabe, A. Ishizaka (Shinanomachi, Shinjuku, Japan). The evaluation of clarithromycin (CAM) in bronchial epithelial lining fluid (ELF) using bronchoscopic microsampling (BMS) probes is useful in the management of patients with pulmonary Mycobacterium avium complex (MAC). Eur Respir J 2005; 26: Suppl. 49, 2904

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Comparison of sputum induction (SI) with fiberoptic bronchoscopy (BFC) in the diagnosis of pulmonary tuberculosis (PTB) Source: Eur Respir J 2001; 18: Suppl. 33, 361s Year: 2001
A gene network to predict the clinical response to whole lung lavage (WLL), in pulmonary alveolar proteinosis (PAP). Source: International Congress 2017 – Novel and old entities Year: 2017
Active bronchial tuberculosis (ABT) among different forms of pulmonary tuberculosis (PT). The retrospective analysis of bronchoscopy data 1998-2001. Source: Eur Respir J 2002; 20: Suppl. 38, 554s Year: 2002
Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by mycobacterium avium-intracellulare complex (MAC) infection Source: Eur Respir J 2003; 22: Suppl. 45, 334s Year: 2003
Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE) Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011
The role of fibreoptic bronchoscopy (FOB) in the diagnosis of active bronchial tuberculosis (ABT) Source: Eur Respir J 2001; 18: Suppl. 33, 497s Year: 2001
Diagnostic contribution of bronchoscopy and bronchial lavage (BL) in pulmonary tuberculosis Source: Annual Congress 2009 - Diagnostic advances in tuberculosis Year: 2009
Microarray and protein biomarker analysis of endobronchial epithelial lining fluid (EELF) in the evaluation of indeterminate pulmonary nodules (IPN) Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010
Clinical significance of Mycobacterium tuberculosis (MBT) DNA detection in bronchoalveolar lavage and bronchial biopsy in HIV-infected patients Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005
Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 655s Year: 2004
The typing of cells in the induced sputum (IS) and its apoptosis in patients with bronchial asthma (BA) Source: Eur Respir J 2002; 20: Suppl. 38, 384s Year: 2002
Bio-Chip (BCh) technology for diagnostics of multidrug resistance (DR) of mycobacterium tuberculosis (MBT) from patients with disseminated tuberculosis (DT) Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Diagnostic value of induced sputum (IS) in interstitial lung disease (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007
Almost half the patients treated for pulmonary tuberculosis (TB) show evidence of obstructive airways disease (OAD) Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control Year: 2007
Characterization of the gene network driving the whole lung lavage (WLL) outcome in Pulmonary Alveolar Proteinosis (PAP). Source: International Congress 2018 – Progress in rare interstitial lung diseases Year: 2018
Diagnostic value of PCR-RT for the detection of DNA Mycobacterium tuberculosis complex (MBT) in blood from patient with pulmonary tuberculosis (PT) Source: Annual Congress 2009 - Diagnostic advances in tuberculosis Year: 2009
Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures Source: International Congress 2016 – Orphan diseases I Year: 2016
Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA). Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017
Safety of sputum induction (SI) in interstitial lung disease (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007
The utility of a serodiagnosis for mycobacterium avium complex pulmonary disease diagnosed by the single available bronchial wash Source: Eur Respir J 2004; 24: Suppl. 48, 206s Year: 2004